Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
TRVN 
Trevena Inc (TRVN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: TRVN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5
1 Year Target Price $5
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -1.11% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 0.88M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 1 | Beta 0.62 | 52 Weeks Range 0.74 - 7.85 | Updated Date 06/30/2025 |
52 Weeks Range 0.74 - 7.85 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -48.89 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1970.67% |
Management Effectiveness
Return on Assets (TTM) -62.39% | Return on Equity (TTM) -1014.58% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 25008977 | Price to Sales(TTM) 1.61 |
Enterprise Value 25008977 | Price to Sales(TTM) 1.61 | ||
Enterprise Value to Revenue 45.8 | Enterprise Value to EBITDA 0.21 | Shares Outstanding 863788 | Shares Floating 858208 |
Shares Outstanding 863788 | Shares Floating 858208 | ||
Percent Insiders 0.48 | Percent Institutions 9.99 |
Analyst Ratings
Rating 1 | Target Price 5 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Trevena Inc
Company Overview
History and Background
Trevena Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel medicines for patients with central nervous system (CNS) disorders. Founded in 2007, it aims to develop biased ligands targeting G protein-coupled receptors (GPCRs).
Core Business Areas
- Pain Management: Focuses on developing and commercializing opioid-sparing pain management therapies.
Leadership and Structure
Carrie Bourdow is the President and CEO. The organizational structure includes departments for research and development, clinical operations, commercialization, and finance.
Top Products and Market Share
Key Offerings
- OLINVYK (oliceridine): OLINVYK is an IV opioid agonist indicated for the management of acute moderate to severe pain in adults when an IV opioid is warranted. Market share is small, in the low single digits, facing competition from established opioids like morphine, fentanyl, and hydromorphone. Competitors include pharmaceutical companies that manufacture and market traditional opioids.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly in the pain management sector, is highly competitive and regulated. There is a growing emphasis on non-opioid and opioid-sparing alternatives to address the opioid crisis.
Positioning
Trevena is positioned as a company developing novel opioid-sparing alternatives, targeting a niche within the pain management market. They aim to reduce opioid-related side effects.
Total Addressable Market (TAM)
The TAM for acute pain management is substantial, estimated to be in the billions of dollars. Trevena's positioning with OLINVYK addresses a segment of this market seeking alternatives to traditional opioids and those with related side effects.
Upturn SWOT Analysis
Strengths
- Novel GPCR-targeted drug development platform
- Potential for opioid-sparing pain management solutions
- Approved product on the market (OLINVYK)
- Strong IP position with its product pipeline
Weaknesses
- Limited financial resources
- Dependence on a single approved product
- Commercial execution risk
- Intense competition from established pharmaceutical companies
Opportunities
- Expansion into additional pain management indications
- Partnerships with larger pharmaceutical companies
- Increasing demand for non-opioid pain alternatives
- Potential for breakthrough therapy designations
Threats
- Regulatory hurdles and delays
- Competition from generic and branded pain medications
- Changing reimbursement landscape
- Clinical trial failures
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- ABBV
Competitive Landscape
Trevena faces significant competition from established pharmaceutical companies with greater resources and broader product portfolios. Its advantage lies in its innovative GPCR-targeted drug development platform.
Growth Trajectory and Initiatives
Historical Growth: Trevena's growth has been reliant on clinical trial progress and commercialization efforts. The approval of OLINVYK marked a significant milestone, but revenue generation has been slow.
Future Projections: Future growth is dependent on the successful commercialization of OLINVYK and the progress of its pipeline. Analyst estimates vary widely due to the inherent uncertainty in biotech investments.
Recent Initiatives: Recent initiatives include expanding the commercial reach of OLINVYK, conducting post-marketing studies, and advancing other pipeline candidates.
Summary
Trevena is a small biopharmaceutical company with an approved product, OLINVYK, but faces significant challenges in commercialization and competition. Its success hinges on expanding OLINVYK's market share and advancing its pipeline. Limited financial resources and intense competition pose risks to its growth. However, there is also opportunity due to rising need for solutions for moderate to severe acute pain that have reduced side effects.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q), Company Website, Press Releases, Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Trevena Inc
Exchange NASDAQ | Headquaters Chesterbrook, PA, United States | ||
IPO Launch date 2014-01-31 | President, CEO & Chairman Ms. Carrie L. Bourdow | ||
Sector Healthcare | Industry Biotechnology | Full time employees 23 | Website https://www.trevena.com |
Full time employees 23 | Website https://www.trevena.com | ||
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.